VTL's CEO and Managing Director, Dr Glenn Tong, said that the founder and senior analyst of Pitt Street Research, Stuart Roberts, was one of the most experienced research analysts in the Australian biotechnology industry.
"We are very pleased that Stuart Roberts has invested time into analysing the VTL story," Dr Tong said.
"Stuart has done a great job in articulating the value proposition which VTL presents and how similar companies have successfully commercialised pharmaceutical products derived from natural sources. He also explains in very clear and simple terms how VTL's drug development and nutraceuticals business will add considerable value to the Company."
To view the report, please visit:
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
VGI Health Technology Limited